U.S., Aug. 12 -- ClinicalTrials.gov registry received information related to the study (NCT07757841) titled 'Real-World Effectiveness of Tezepelumab in Allergic Bronchopulmonary Aspergillosis' on July 31.
Brief Summary: An open-label study will evaluate effects of Tezepelumab in the treatment of severe asthma in patients with allergic bronchopulmonary aspergillosis
Study Start Date: Sept. 01
Study Type: INTERVENTIONAL
Condition:
Allergic Bronchopulmonary Aspergillosis
Severe Asthma
ABPA
Intervention:
DRUG: Tezepelumab
210 mg (1.91 mL) Subcutaneous Solution
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Qianfoshan Hospital
Information provided by (Responsible Party): Qian Qi, Qianfoshan Hospital
Disclaimer: Curated by HT Syndica...